GE HealthCare Technologies reported fourth‐quarter revenue of $5.7 billion, up 7.1% year-over-year, and non-GAAP EPS of $1.44, surpassing consensus estimates of $5.61 billion and $1.40, respectively. Organic revenue growth was 4.8%, driven primarily by higher demand in the U.S. and EMEA. Net income attributable to GE HealthCare was $589 million, and adjusted EBIT reached $950 million. Despite a 320-basis-point decline in net income margin to 10.3% and a 200-basis-point drop in adjusted EBIT margin to 16.7% due to tariff headwinds and mix shifts, management highlighted that volume gains and pricing initiatives partially offset these pressures.

The Imaging segment delivered $2.55 billion in sales, up 6.6% (5.3% organic), while Advanced Visualization Solutions grew 5.9% to $1.53 billion. Pharmaceutical Diagnostics surged 22.3% (12.7% organic) to $790 million, propelled by new assay launches and strong order flow. Patient Care Solutions was flat at $825 million. Innovation efforts include the cloud-first Allia Moveo mobile C-arm platform, AI‐driven imaging workflows and the planned $2.3 billion acquisition of Intelerad, which will expand the company’s enterprise imaging capabilities across care settings.

Shares trade at an attractive multiple relative to peers, reflecting both recent outperformance and a valuation near fair value in absolute terms. GE HealthCare ended 2025 with $4.5 billion in cash, $3.5 billion of revolver capacity and $10.0 billion of debt, while returning $200 million through share repurchases. For fiscal 2026, the company forecasts adjusted EPS of $4.95–$5.15 (consensus $4.92), organic revenue growth of 3.0%–4.0%, and adjusted EBIT margin expansion of 50–80 basis points, with tariff impacts expected to diminish year-over-year.